NASH PASS is a clinical research platform providing healthcare providers and clinical trial sites the tools, methodology, and support to diagnose and monitor at-risk patients for the progression of fatty liver disease and nonalcoholic steatohepatitis (NASH). The program also provides qualified principal investigators and diagnosed patients the opportunity to participate in clinical trials investigating new NASH drug candidates. For sponsors, NASH PASS is highly effective in optimizing I/E criteria, substantially improving patient access and enrollment, and streamlining site selection for NASH clinical trials.
NASH PASS Integrates Three Science-Driven Elements:
Clinical Research
Methodology
ProSciento’s NASH PASS is a unique program that combines a scientific methodology, clinical protocol, patient registry and biobank, designed to enhance medical knowledge related to fatty liver disease progression, diagnostic biomarkers, and clinical research.
Clinical Study Protocol
ProSciento provides clinical trial sites and healthcare providers access to advanced diagnostic capabilities to screen at-risk patients for fatty liver conditions. The NASH PASS screening protocol is used to determine a diagnosis, guide decisions regarding liver biopsy, and determine a patient’s eligibility for a clinical study.
Patient Registry
The NASH PASS registry is comprised of confirmed patient diagnoses enriched with a broad range of assessments. The real-time and longitudinal data is utilized for NASH clinical trial enrollment and to support biomarker and disease progression research.
